请参阅随附的OJJAARA完整处方信息: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4a672fd1-eb7b-4aa9-9b23-845e4b5dc400
--------------------------------------------
Ojjaara (momelotinib)approved in the US as the first and only treatment indicated for myelofibrosis patients with anemia
US Food and Drug Administration (FDA) has approved Ojjaara (momelotinib) for the treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post-polycythemia vera and post-essential thrombocythemia), in adults with anemia.
PRINCIPAL DISPLAY PANEL
NDC 81864-102-30
Ojjaara(momelotinib)tablets
150 mg
Rx Only
GSK
30 Tablets
Each 150 mg tablet is equivalent to 182.9 mg of momelotinib dihydrochloride monohydrate. Swallow tablets whole.
Do not cut, crush, or chew tablets.
Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). (see USP Controlled Room Temperature). Dispense and store in original bottle with desiccant to protect from moisture.